Irvine medical device maker Ivantis Inc. said today that it has raised $5 million more in a second round of venture funding.
Ivantis said it would use the money to support three multinational clinical trials for its Hydrus microstent, which is implanted into the eye to treat glaucoma. Glaucoma is a major cause of blindness, affecting more than 60 million people worldwide.
The device maker added that it would use some of the money to support its activities in the Asia-Pacific market.
EDBI, a Singaporean firm, led the round’s close.
Ivantis was established in 2007. The company said the new money brings the total second round of funding to $32.5 million.
